Literature DB >> 23430094

Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

J-C Kim1, S-H Shin, H G Yi, S-H Kim, S-I Woo, D-H Kim, K-S Park, J Kwan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23430094     DOI： 10.1007/s00059-013-3765-7

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


× No keyword cloud information.
  10 in total

Review 1.  Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

Authors:  Walid Rasheed; Brendan Flaim; John F Seymour
Journal:  Leuk Res       Date:  2008-11-04       Impact factor: 3.156

3.  Reversal of experimental pulmonary hypertension by PDGF inhibition.

Authors:  Ralph Theo Schermuly; Eva Dony; Hossein Ardeschir Ghofrani; Soni Pullamsetti; Rajkumar Savai; Markus Roth; Akylbek Sydykov; Ying Ju Lai; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.

Authors:  D Dumitrescu; C Seck; Henrik ten Freyhaus; F Gerhardt; E Erdmann; S Rosenkranz
Journal:  Eur Respir J       Date:  2011-07       Impact factor: 16.671

5.  Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.

Authors:  Ester M Orlandi; Barbara Rocca; Anna S Pazzano; Stefano Ghio
Journal:  Leuk Res       Date:  2011-09-03       Impact factor: 3.156

6.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Neil P Shah; Andreas Hochhaus; Jorge Cortes; Sandip Shah; Manuel Ayala; Beatriz Moiraghi; Zhixiang Shen; Jiri Mayer; Ricardo Pasquini; Hirohisa Nakamae; Françoise Huguet; Concepción Boqué; Charles Chuah; Eric Bleickardt; M Brigid Bradley-Garelik; Chao Zhu; Ted Szatrowski; David Shapiro; Michele Baccarani
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

7.  Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Authors:  Anne Bergeron; Delphine Réa; Vincent Levy; Clément Picard; Véronique Meignin; Jérome Tamburini; Heriberto Bruzzoni-Giovanelli; Fabien Calvo; Abdellatif Tazi; Philippe Rousselot
Journal:  Am J Respir Crit Care Med       Date:  2007-06-28       Impact factor: 21.405

8.  Role of Src tyrosine kinases in experimental pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Eva Maria Berghausen; Swati Dabral; Aleksandra Tretyn; Elsa Butrous; Rajkumar Savai; Ghazwan Butrous; Bhola Kumar Dahal; Ralf P Brandes; Hossein Ardeschir Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Stephan Rosenkranz; Ralph Theo Schermuly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-19       Impact factor: 8.311

9.  Pulmonary arterial hypertension in patients treated by dasatinib.

Authors:  David Montani; Emmanuel Bergot; Sven Günther; Laurent Savale; Anne Bergeron; Arnaud Bourdin; Helene Bouvaist; Matthieu Canuet; Christophe Pison; Margareth Macro; Patrice Poubeau; Barbara Girerd; Delphine Natali; Christophe Guignabert; Frédéric Perros; Dermot S O'Callaghan; Xavier Jaïs; Pascale Tubert-Bitter; Gérard Zalcman; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Circulation       Date:  2012-03-26       Impact factor: 29.690

10.  Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Authors:  Jan K Hennigs; Gunhild Keller; Hans Jörg Baumann; Friedemann Honecker; Stefan Kluge; Carsten Bokemeyer; Tim H Brümmendorf; Hans Klose
Journal:  BMC Pulm Med       Date:  2011-05-23       Impact factor: 3.317
  10 in total
  1 in total

Review 1.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.